Interactions between neuropeptides and dopamine neurons in the ventromedial mesencephalon.
Cholecystokinin (CCK), enkephalin, neurotensin (NT), substance P (SP) and substance K (SK) are five neuropeptides that exist in neuronal perikarya or fibers in the vicinity of the A10 dopamine neurons in the ventromedial mesencephalon. Based upon this anatomical proximity, many investigations have been evaluating the possibility that these peptides may influence the function of the A10 dopamine neurons. A variety of experimental techniques have been employed in this regard, including anatomical, electrophysiological, neurochemical and behavioral methodologies. Measurement of immunoreactive peptide levels with radioimmunoassay, and visualization of peptidergic neurons and fibers with immunocytochemistry has demonstrated not only that peptides exist in the vicinity of A10 dopamine neurons, but using double labeling techniques NT and CCK have been found to coexist with dopamine in the same neuron. Further, by combining retrograde tracing technique with immunocytochemistry, the origin of some peptidergic afferents to the ventromedial mesencephalon has been determined. With the exception of CCK-8, microinjection into the ventromedial mesencephalon of rats with all the peptides or potent analogues produces a dose-related increase in spontaneous motor activity. For SP, NT and enkephalin the motor response has been blocked by dopamine antagonists. Further, an increase in dopamine metabolism in mesolimbic dopamine terminal fields is produced concurrent with the behavioral hyperactivity. These data indicate that SP, SK, enkephalin and NT can activate dopamine neurons in the ventromedial mesencephalon. This postulate is supported by electrophysiological studies showing an excitatory action by iontophoretic administration of peptide onto dopamine neurons. However, in some studies, excitatory electrophysiological effects were not observed. While some observations are contradictory, sufficient data has accumulated that tentative postulates and conclusions can be made about how these peptides may influence the A10 dopamine neurons. Further, speculations are offered as to the role this modulatory action may play in the many behaviors and pathologies thought to involve these dopamine neurons.
P W
PW
Kalivas
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002415:Cats; D002766:Cholecystokinin / Q000494:pharmacology / Q000502:physiology; D004298:Dopamine / Q000502:physiology*; D004745:Enkephalins / Q000494:pharmacology / Q000502:physiology; D000882:Haplorhini; D006801:Humans; D008032:Limbic System / Q000187:drug effects; D008636:Mesencephalon / Q000187:drug effects / Q000502:physiology*; D009419:Nerve Tissue Proteins / Q000494:pharmacology / Q000502:physiology*; D015288:Neurokinin A; D009496:Neurotensin / Q000494:pharmacology / Q000502:physiology; D051381:Rats; D012559:Schizophrenia / Q000209:etiology; D013373:Substance P / Q000494:pharmacology / Q000502:physiology; D013552:Swine
D004745:Enkephalins; D009419:Nerve Tissue Proteins; D013373:Substance P; D009496:Neurotensin; D015288:Neurokinin A; D002766:Cholecystokinin; D004298:Dopamine